Skip to main content
Wolfram Samlowski, MD, Oncology, Las Vegas, NV

WolframESamlowskiMD

Oncology Las Vegas, NV

Clinical Professor of Medicine at University of Nevada School of Medicine.

Dr. Samlowski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Samlowski's full profile

Already have an account?

  • Office

    9280 W Sunset Rd
    Ste 100
    Las Vegas, NV 89148
    Phone+1 702-952-1251
    Fax+1 702-952-1242

Education & Training

  • University of Utah Health
    University of Utah HealthFellowship, Hematology and Medical Oncology, 1981 - 1984
  • Wayne State University School of Medicine
    Wayne State University School of MedicineResidency, Internal Medicine, 1978 - 1981
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 1978

Certifications & Licensure

  • UT State Medical License
    UT State Medical License 1981 - 2026
  • NV State Medical License
    NV State Medical License 2007 - 2025
  • MI State Medical License
    MI State Medical License 1979 - 1984
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Vegas Seven Castle Connolly, 2014
  • America's Top Doctors Castle Connolly, 2009-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Introducing Vegas Inc’s 2021 Top Doctors
    Introducing Vegas Inc’s 2021 Top DoctorsAugust 26th, 2021
  • Health Care Quarterly’s 2020 Top Doctors
    Health Care Quarterly’s 2020 Top DoctorsAugust 20th, 2020

Grant Support

  • Epigenetic Potentiation Of Interferon Using DecitabineNational Cancer Institute2007–2008
  • Phase I Trial Of Php With High-Dose IL-2National Cancer Institute2006
  • Phase I Trial Of Php With High-Dose IL-2National Cancer Institute2005–2006
  • Southwest Oncology Group (UTAH)National Cancer Institute1993–2003
  • Toxicity Of Continuous Infusion N Acetyl Cysteine With High Dose IL2National Center For Research Resources1998–2002
  • Nitric Oxide As A Tumor DefenseNational Cancer Institute1997–1999
  • Toxicity Of Continuous Infusion N-Acetyl Cysteine With High Dose IL-2National Center For Research Resources1995–1997
  • Phase II Trial--Il-2 Treatment Of Relapsed Or Refractory ANLLNational Center For Research Resources1996
  • FACS Vantage Cell SorterNational Center For Research Resources1995
  • Use Of Sulfhydryl Compounds To Increase IL-2 ActivityNational Cancer Institute1992–1994
  • Endothelial Cell Toxicity Of Marrow Ablative AgentsNational Cancer Institute1988–1992

Professional Memberships